N

Ningbo Menovo Pharmaceutical Co Ltd
SSE:603538

Watchlist Manager
Ningbo Menovo Pharmaceutical Co Ltd
SSE:603538
Watchlist
Price: 13.09 CNY -5.56% Market Closed
Market Cap: 2.8B CNY
Have any thoughts about
Ningbo Menovo Pharmaceutical Co Ltd?
Write Note

Ningbo Menovo Pharmaceutical Co Ltd
Total Liabilities & Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Ningbo Menovo Pharmaceutical Co Ltd
Total Liabilities & Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities & Equity CAGR 3Y CAGR 5Y CAGR 10Y
N
Ningbo Menovo Pharmaceutical Co Ltd
SSE:603538
Total Liabilities & Equity
ÂĄ4.4B
CAGR 3-Years
12%
CAGR 5-Years
14%
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Total Liabilities & Equity
ÂĄ33B
CAGR 3-Years
17%
CAGR 5-Years
31%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Total Liabilities & Equity
ÂĄ17B
CAGR 3-Years
16%
CAGR 5-Years
17%
CAGR 10-Years
18%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Total Liabilities & Equity
ÂĄ48.2B
CAGR 3-Years
7%
CAGR 5-Years
13%
CAGR 10-Years
19%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Total Liabilities & Equity
ÂĄ54.4B
CAGR 3-Years
3%
CAGR 5-Years
3%
CAGR 10-Years
15%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Total Liabilities & Equity
ÂĄ1.4B
CAGR 3-Years
11%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Ningbo Menovo Pharmaceutical Co Ltd
Glance View

Market Cap
2.9B CNY
Industry
Pharmaceuticals

Ningbo Menovo Pharmaceutical Co., Ltd. engages in the research, development, testing, production, and sale of pharmaceutical products. The company is headquartered in Ningbo, Zhejiang and currently employs 2,473 full-time employees. The company went IPO on 2017-04-07. The Company’s products contain gastropathic medicine and cardiovascular medicine, which include anti-hypertension medicine, anti-hyperlipidemia medicine and anti-thrombus medicine. The firm distributes its products to both domestic and overseas markets.

Intrinsic Value
12.45 CNY
Overvaluation 5%
Intrinsic Value
Price
N

See Also

What is Ningbo Menovo Pharmaceutical Co Ltd's Total Liabilities & Equity?
Total Liabilities & Equity
4.4B CNY

Based on the financial report for Dec 31, 2023, Ningbo Menovo Pharmaceutical Co Ltd's Total Liabilities & Equity amounts to 4.4B CNY.

What is Ningbo Menovo Pharmaceutical Co Ltd's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 5Y
14%

Over the last year, the Total Liabilities & Equity growth was 0%. The average annual Total Liabilities & Equity growth rates for Ningbo Menovo Pharmaceutical Co Ltd have been 12% over the past three years , 14% over the past five years .

Back to Top